Watch Out GSK: Vectura And Hikma Target Ellipta Portfolio
Vectura and Hikma could have generic versions of GSK's Ellipta portfolio ready for marketing when patent protection expires.
Vectura and Hikma could have generic versions of GSK's Ellipta portfolio ready for marketing when patent protection expires.